Randomized trial · people

Thymosin alpha-1 lowered infections after colorectal cancer surgery

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this trial, thymalfasin added to post-surgery chemotherapy was linked to fewer infections and complications in colorectal cancer patients, and the twice-weekly and three-times-weekly schedules gave similar infection results.

Kind
Randomized trial
Studied in
People
Number studied
400
Published
2024
Journal
Biotechnol Genet Eng Rev

What they tested

The team tested whether thymalfasin injections, given with chemotherapy, improve immune function around surgery and long-term outcomes in people having colorectal cancer surgery.

How the study was done

A randomized controlled trial in 400 patients who had surgery to remove colorectal cancer at one hospital. Patients were randomly assigned to a chemotherapy regimen called XELOX alone or XELOX plus thymalfasin, and the thymalfasin patients were split into a conventional-dose group (n = 100, 1.6 mg twice a week) and a high-dose group (n = 100, 1.6 mg three times a week).

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking Thymosin Alpha-1? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Both thymalfasin groups had significantly fewer infections around the time of surgery than the chemotherapy-only group, and the two dose groups did not differ from each other. The thymalfasin patients as a whole also had fewer early and late complications after surgery, less local recurrence (cancer returning at the original site) and less distant metastasis (spread to other organs). They also scored higher on immune function indexes around surgery and had a longer median disease-free survival, the time patients lived without the cancer coming back.

What it doesn’t show

This was a single-hospital trial, and the comparison group got chemotherapy alone rather than a dummy injection. The results apply to colorectal cancer patients on XELOX after surgery, not to other people or uses.

The paper

Niu et al. A Prospective and Randomized Control Study on Effects of Thymalfasin for Injection on Perioperative Immune Function and Long-term Prognosis of Patients with Colorectal Cancer. Biotechnol Genet Eng Rev. 2024.

The compound

More studies on Thymosin Alpha-1

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking Thymosin Alpha-1? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo